Essa Pharma Stock Buy Hold or Sell Recommendation
| EPIX Stock | USD 6.72 0.35 4.95% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding ESSA Pharma is 'Strong Sell'. Macroaxis provides ESSA Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding EPIX positions. The advice algorithm takes into account all of ESSA Pharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting ESSA Pharma's buy or sell advice are summarized below:
Real Value 9.76 | Target Price 19.4 | Hype Value 6.61 | Market Value 6.72 | Naive Value 6.84 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell ESSA Pharma given historical horizon and risk tolerance towards ESSA Pharma. When Macroaxis issues a 'buy' or 'sell' recommendation for ESSA Pharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
ESSA |
Execute ESSA Pharma Buy or Sell Advice
The ESSA recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ESSA Pharma. Macroaxis does not own or have any residual interests in ESSA Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ESSA Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
ESSA Pharma Trading Alerts and Improvement Suggestions
| ESSA Pharma generated a negative expected return over the last 90 days | |
| ESSA Pharma has high historical volatility and very poor performance | |
| Net Loss for the year was (26.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ESSA Pharma currently holds about 174.6 M in cash with (19.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96. | |
| ESSA Pharma has a very weak financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Hedge funds investors in ESSA Pharma Inc. lost 12 percent last week but have reaped the benefits of longer-term growth |
ESSA Pharma Returns Distribution Density
The distribution of ESSA Pharma's historical returns is an attempt to chart the uncertainty of ESSA Pharma's future price movements. The chart of the probability distribution of ESSA Pharma daily returns describes the distribution of returns around its average expected value. We use ESSA Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ESSA Pharma returns is essential to provide solid investment advice for ESSA Pharma.
| Mean Return | -0.33 | Value At Risk | -7.29 | Potential Upside | 7.71 | Standard Deviation | 5.10 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ESSA Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ESSA Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ESSA Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ESSA Pharma backward and forwards among themselves. ESSA Pharma's institutional investor refers to the entity that pools money to purchase ESSA Pharma's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cibc World Markets Inc. | 2023-12-31 | 111.7 K | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 57.5 K | Royal Bank Of Canada | 2023-12-31 | 30.8 K | Geode Capital Management, Llc | 2023-12-31 | 26.9 K | Renaissance Technologies Corp | 2023-12-31 | 24.2 K | American Century Companies Inc | 2023-12-31 | 20 K | Privium Fund Management (uk) Ltd | 2023-12-31 | 20 K | Group One Trading, Lp | 2023-12-31 | 11.2 K | Blackrock Inc | 2023-12-31 | 7.7 K | Bvf Inc | 2023-09-30 | 8.7 M | Bellevue Group Ag | 2023-12-31 | 7.9 M |
ESSA Pharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (21.7M) | (35.0M) | (52.3M) | (3.5M) | (3.2M) | (3.3M) | |
| Change In Cash | 3.0M | 81.5M | (80.7M) | (23.4M) | (21.0M) | (20.0M) | |
| Net Borrowings | (2.8M) | (4.0M) | (100.3K) | (134.0K) | (120.6K) | (114.6K) | |
| Depreciation | 110.3K | 109.5K | 121.8K | 118.5K | 136.3K | 68.8K | |
| Net Income | (23.4M) | (36.8M) | (35.1M) | (26.6M) | (23.9M) | (25.1M) | |
| End Period Cash Flow | 56.3M | 137.8M | 57.1M | 33.7M | 38.8M | 37.2M | |
| Change To Netincome | 1.8M | 7.6M | 9.3M | 7.1M | 8.1M | 8.5M | |
| Free Cash Flow | (17.0M) | (25.4M) | (28.7M) | (19.8M) | (17.8M) | (18.7M) | |
| Other Non Cash Items | 224.1K | (35.3K) | (830.8K) | 7.3K | 8.4K | 8.8K |
ESSA Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ESSA Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ESSA Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ESSA stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.4 | |
β | Beta against NYSE Composite | 0.99 | |
σ | Overall volatility | 5.10 | |
Ir | Information ratio | -0.08 |
ESSA Pharma Volatility Alert
ESSA Pharma exhibits very low volatility with skewness of -0.86 and kurtosis of 5.26. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ESSA Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ESSA Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.ESSA Pharma Fundamentals Vs Peers
Comparing ESSA Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ESSA Pharma's direct or indirect competition across all of the common fundamentals between ESSA Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as ESSA Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ESSA Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing ESSA Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ESSA Pharma to competition |
| Fundamentals | ESSA Pharma | Peer Average |
| Return On Equity | -0.17 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Current Valuation | 171.02 M | 16.62 B |
| Shares Outstanding | 44.24 M | 571.82 M |
| Shares Owned By Insiders | 2.20 % | 10.09 % |
| Shares Owned By Institutions | 78.71 % | 39.21 % |
| Number Of Shares Shorted | 802.84 K | 4.71 M |
| Price To Earning | (1.12) X | 28.72 X |
| Price To Book | 2.48 X | 9.51 X |
| EBITDA | (26.46 M) | 3.9 B |
| Net Income | (26.58 M) | 570.98 M |
| Cash And Equivalents | 174.6 M | 2.7 B |
| Cash Per Share | 3.96 X | 5.01 X |
| Total Debt | 80.33 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 43.43 X | 2.16 X |
| Book Value Per Share | 3.19 X | 1.93 K |
| Cash Flow From Operations | (19.78 M) | 971.22 M |
| Short Ratio | 11.26 X | 4.00 X |
| Earnings Per Share | (0.59) X | 3.12 X |
| Target Price | 19.0 | |
| Number Of Employees | 50 | 18.84 K |
| Beta | 1.69 | -0.15 |
| Market Capitalization | 297.28 M | 19.03 B |
| Total Asset | 149.12 M | 29.47 B |
| Retained Earnings | (179.46 M) | 9.33 B |
| Working Capital | 145.3 M | 1.48 B |
| Current Asset | 10.02 M | 9.34 B |
| Current Liabilities | 3.63 M | 7.9 B |
| Net Asset | 149.12 M |
Note: Acquisition by Cesano Alessandra of 200000 shares of ESSA Pharma at 9.04 subject to Rule 16b-3 [view details]
ESSA Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ESSA . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About ESSA Pharma Buy or Sell Advice
When is the right time to buy or sell ESSA Pharma? Buying financial instruments such as ESSA Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Cash | 57.1M | 33.7M | 38.8M | 37.2M | Accounts Payable | 954.6K | 2.0M | 2.3M | 1.6M |
Use Investing Ideas to Build Portfolios
In addition to having ESSA Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Defense Thematic Idea Now
Defense
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Defense theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Defense Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ESSA Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for ESSA Stock analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.13) | Return On Equity (0.17) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.